Skip to content
mielomamultiplo.com · Multiple Myeloma
Emergency 112  · SNS 24 808 24 24 24
The Multiple Myeloma symbol — find out what it means

Multiple Myeloma There is hope. There is a way forward.

information · support · hope

It is always better to be an informed patient.

News, testimonies, a space to share ideas and links that help patients and carers understand the disease better and know where to find help.

Automatic translation by MielomaAI. The original text is in Portuguese. Some parts may still appear in Portuguese while they are being translated. Português
What Infarmed decided about myeloma

O InfarmedThe drug authority in Portugal. Before the SNS pays for a new medicine, it assesses whether it is better than what already exists and whether the price is fair. Assess each new medication, and each new way of using it, before hospitals within the SNS can prescribe it. This page brings together what the Infarmed has published about multiple myeloma: 25 treatments approved, the rejected, those who are Early accessEarly Access Programme (EAP): allows the use of a medicine before the financing decision is made, in patients without alternative options, with authorization from Infarmed. And where the treatments are carried out.

Sources: a search for “multiple myeloma” on the Infarmed website (204 results, of which approximately 40 are reports and decisions regarding myeloma medications; the others are monthly statistics, newsletters and documents on other diseases), the list of new medicines with public funding and the list of PAPs (both as of 19/03/2026), and the decisions published until 14/10/2026. Summaries made by the website from the reports; do not replace your medical team.

How to read the reviews

Added therapeutic value � How much better is the new drug than the usual treatment? Larger considerable / moderate less than / not quantifiable / suggestion not demonstrated / equivalentUnquantifiable" means there is benefit but studies don't allow us to say how much. Test result quality � How confident are the experts (high, moderate, low, very low)? HR � compare the risk: HR 0.50 means half the risk of the disease progressing (or dying) at any given time.

Approved and reimbursed treatments by the SNS. 25

All are for hospital use: the decision to use is made by the hematology team, within the approved conditions. Tap on a treatment to see the summary.

First treatment – who can do the transplant

Velcade (bortezomib) � With dexamethasone, with or without VTd/VD (talidomide) in induction prior to transplant · approved on 12/04/2017 Added value demonstratedThe medication showed to be better than usual, to a moderate degree (or with added value demonstrated).

Better responses and more time without the disease progressing than older treatments (VAD, TD); it has not been shown to prolong life.

Test result quality: — · Conditions: Hospital Use. · Infarmed report ↗

Darzalex (daratumumab) � With bortezomib, talidomide and dexamethasone (Dara-VTd) · approved on 28/03/2022 Non quantifiableNon-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

In the CASSIOPEIA study, more complete and rigorous answers (29% versus 20%) and less risk of the disease progressing (HR 0.47) compared to VTd.

Test result quality: low to moderate Conditions: Only in this combination, in patients undergoing transplantation. Infarmed report ↗

Melfalano Teva (melfalano) � At high doses, before an autologous transplant (and at conventional doses) · approved on 25/02/2019 Equivalent to the existing melfalan.It has not been shown to be better than standard treatment (or was considered equivalent). It may have been approved due to its lower cost.

Considered equivalent to the previous melfalano, at a lower cost.

Test result quality: — · Conditions: Hospital Use. · Infarmed report ↗

plerixafor � With G-CSF, to collect stem cells when the first attempt failed · approved on 24/05/2011 There exists, difficult to quantify.Non-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

Help to obtain enough cells for transplant in “mobilizing powerhouses”; no demonstrated difference in survival.

Test result quality: limited Conditions: Only after failing a first mobilization. Infarmed report ↗

Maintenance after transplant

Revlimid (lenalidomide) � Alone, as maintenance after an autotransplant · approved on 30/09/2019 Non quantifiableNon-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

Delays the return of the disease; it has not been proven to prolong life, and there are more side effects and secondary cancers. National guidelines recommend at least 12 cycles, ideally up to 36.

Test result quality: Informal · Conditions: Hospital Use. · Infarmed report ↗

First treatment – for those who cannot undergo transplant

Velcade (bortezomib) � With melfalano and prednisone (VP) · approved on 12/04/2017 Equivalent to MPPIt has not been shown to be better than standard treatment (or was considered equivalent). It may have been approved due to its lower cost.

Considered equivalent to the bortezomib scheme (MPT). In the national guidelines, it is the first choice for those who are 70 years or older or who cannot undergo transplantation.

Test result quality: — · Conditions: Hospital Use. · Infarmed report ↗

Darzalex (daratumumab) � With bortezomib, melfalan and prednisone (Dara-VMP) · approved on 28/03/2022 Larger (non-high genetic risk)Greater therapeutic added value: The Infarmed considered that the medicine is clearly better than the standard treatment.

In patients without high-risk genetic alterations, there is a lower risk of death (HR 0.54) and the disease progressing (HR 0.35). In high-risk patients, no benefit has been demonstrated.

Test result quality: Moderate Conditions: Only for patients WITHOUT high-risk cytogenetic alterations. · Infarmed report ↗

Darzalex (daratumumab) � With lenalidomide and dexamethasone (Dara-Rd) · approved on 28/03/2022 Moderate (relative to RPM); lower (relative to VMP)The medication showed to be better than usual, to a moderate degree (or with added value demonstrated).

In indirect comparisons, less risk of death (HR 0.60 compared to VMP; 0.61 compared to MPT).

Test result quality: indirect comparison Conditions: Hospital Use. · Infarmed report ↗

Revlimid (lenalidomide) � With dexamethasone, without prior treatment · approved on 10/12/2021 Added valueThe medication showed to be better than usual, to a moderate degree (or with added value demonstrated).

It delayed the disease progression more than the MPS.

Test result quality: — · Conditions: Hospital Use. · Infarmed report ↗

Sarclisa (isatuximab) � With bortezomib, lenalidomide and dexamethasone (Isa-VRd) · approved on 30/09/2026 Not applicableIt has not been shown to be better than standard treatment (or was considered equivalent). It may have been approved due to its lower cost.

It has not been proven to be better than regimens with daratumumab; it was approved mainly due to its lower cost for the NHS.

Test result quality: very low Conditions: In-patient use, with contract. Infarmed report ↗

Thalidomide � With melfalan and prednisone (MPT), in patients aged 65 or older · approved on 24/02/2011 Added value demonstratedThe medication showed to be better than usual, to a moderate degree (or with added value demonstrated).

In a main study, patients lived longer. There are strict rules, including a pregnancy prevention program.

Test result quality: — · Conditions: Neuropathy and clot monitoring. Infarmed report ↗

When the disease returns (1 to 3 previous treatments)

Revlimid (lenalidomide) � With dexamethasone (Rd) · approved on 30/01/2009 —Non-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

It was neither better nor worse than bortezomib, but with less neuropathy.

Test result quality: initial evidence Conditions: Selection and suspension criteria. · Infarmed report ↗

Darzalex (daratumumab) � With lenalidomide and dexamethasone (Dara-Rd) · approved on 28/12/2018 Non quantifiableNon-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

Pollux Study: lower risk of disease progression (HR 0.37); more neutropenia and infections.

Test result quality: Informal · Conditions: Hospital Use. · Infarmed report ↗

Darzalex (daratumumab) � With bortezomib and dexamethasone (Dara-Vd) · approved on 22/03/2019 Non quantifiableNon-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

CASTOR Study: Much more time without disease progression.

Test result quality: Informal · Conditions: Up to 75 years old with less than 3 prior lines, or with high genetic risk. Infarmed report ↗

Kyprolis (carfilzomib) � With lenalidomide and dexamethasone (KRd) · approved on 2018/10/01 ModerateThe medication showed to be better than usual, to a moderate degree (or with added value demonstrated).

ASPIRE Study: More Time Without Disease Progression.

Test result quality: Informal · Conditions: Cannot have progressed or be refractory to bortezomib; ECOG 2 or less; other criteria for lenalidomide. Infarmed report ↗

Kyprolis (carfilzomib) � With dexamethasone (dexamethasone) · approved on 2020/07/15 Lower (compared to you); suggested benefit (compared to them)Non-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

ENDEAVOR Study: 18.7 versus 9.4 months without disease progression compared to bortezomib (HR 0.53); more severe adverse events.

Test result quality: moderate / low Conditions: In-patient use, with contract. Infarmed report ↗

Ninlaro (ixazomib) � With lenalidomide and dexamethasone (IxarD), all in tablet form · approved on 2019/07/16 Non quantifiableNon-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

Delayed progression without increasing adverse effects; no demonstrated survival benefit.

Test result quality: Informal · Conditions: Hospital Use. · Infarmed report ↗

Imnovid (pomalidomide) � With bortezomib and dexamethasone (PVd), previously treated with lenalidomide · approved on 26/03/2024 Non quantifiableNon-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

OPTIMISMM Study: 11.2 versus 7.1 months without disease progression (HR 0.61). Approved following price reduction.

Test result quality: Moderate Conditions: In-patient use, with contract. Infarmed report ↗

Sarclisa (isatuximab) � With carfilzomib and dexamethasone (Isa-Kd) · approved on 30/09/2026 Benefit versus Kd; not demonstrated versus Dara-VdIt has not been shown to be better than standard treatment (or was considered equivalent). It may have been approved due to its lower cost.

In the face of carfilzomib and dexamethasone, there is a lower risk of the disease progressing (HR 0.53).

Test result quality: not graduated Conditions: In-patient use, with contract. Infarmed report ↗

Resistant (refractory) disease and 3 or more treatments

Imnovid (pomalidomide) � With dexamethasone (Pd), in double refractory status · approved on 26/09/2019 Suggestion, not quantifiableNon-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

For those who no longer respond to lenalidomide nor bortezomib.

Test result quality: — · Conditions: Refractory to a proteasome inhibitor and an immunomodulator. Infarmed report ↗

Darzalex (daratumumab) � Alone, after proteasome inhibitor and immunomodulator · approved on 28/12/2018 Suggestion, not quantifiableNon-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

In studies, approximately 31% of patients responded.

Test result quality: Without a comparative study Conditions: Hospital Use. · Infarmed report ↗

Sarclisa (isatuximab) � With pomalidomide and dexamethasone (Isa-Pd), refractory to lenalidomide · approved on 27/01/2022 Non quantifiableNon-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

ICARIA Study: 11.5 versus 6.5 months without disease progression (HR 0.60); 60% versus 35% response rates.

Test result quality: Phase 3 trial · Conditions: Only patients refractory to lenalidomide, with 2 or more treatments. Infarmed report ↗

Carvykti (cell-based, CAR-T) � After 3 or more treatments (immunomodulatory, proteasome inhibitor, and anti-CD38) · approved on 26/05/2025 LargestGreater therapeutic added value: The Infarmed considered that the medicine is clearly better than the standard treatment.

In light of standard treatment: 28 versus 4 months without the disease progressing (HR 0.19). Approved after the price was lowered.

Test result quality: Moderate Conditions: Only performed in qualified CAR-T centers (see below). Infarmed report ↗ · detailed explanation →

Tecvayli (teclistamab, biespecific) � Alone, after 3 or more treatments · approved for 29/12/2025 Suggestion, not quantifiableNon-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

Indirec comparison: 11.3 versus 4.1 months without progression of the disease (HR 0.48); survival still immature. Approved after price reduction.

Test result quality: low Conditions: Hospital care; starts with increasing doses and monitoring. Infarmed report ↗

Elrexfio (elranatamab, biespecific) � Alone, after 3 or more treatments · approved on 2026-08-17 Suggestion, not quantifiableNon-quantifiable: there is evidence that the drug is better than standard treatment, but studies do not allow us to say how much better (for example, because there is no direct comparison, data is still immature or there are few patients). “Suggestive” means the evidence is even weaker.

Indirect comparison: 76% versus 34% of responses. Approved after price reduction.

Test result quality: low Conditions: Day hospital with a team to manage cytokine release syndrome and neurotoxicity; 48-hour monitoring after the first two doses. Infarmed report ↗

Early access or still deciding.

It’s… Early Access ProgramThe Infarmed authorizes the use of a medication before the final decision, on a case-by-case basis, in patients with no alternative. List of Multiple Myeloma PAPs (Infarmed, 03/19/2026):

MedicineDecisionFor whomPatientsToday
Talvey (talquetamab, biespecific)PAP approved
23/11/2023
Following 3 or more treatments (immunomodulatory, proteasome inhibitor, and anti-CD38).10Still no funding decision published.
Elrexfio (elranatamab)PAP approved
01/02/2024
After 3 or more treatments25Funding approved on 2026-08-17.
Darzalex (daratumumab) + pomalidomide + dexamethasonePAP approved
11/11/2021
Refractory to immunomodulators and proteasome inhibitors2Access as needed.
Kyprolis (carfilzomib) + daratumumab + dexamethasonePAP approved
25/06/2021
Refractory or contraindicated to lenalidomide and bortezomib.8Access as needed.
Sarclisa (isatuximab) + carfilzomib + dexamethasonePAP approved
16/03/2023
Refractory or contraindicated to lenalidomide and bortezomib.—Funding approved on 30/09/2026.
Darzalex (daratumumab) + bortezomib + lenalidomide + dexamethasone (Dara-VRd)PAP does not accept
13/11/2025
First treatment for those eligible for transplant—The Infarmed has concluded that it did not fall within the early access exception; it follows the normal assessment.

Approved in Europe but without a funding decision published in Portugal. (as of 14/10/2026, in the Infarmed lists): talquetamab (Talvey) and linvoseltamab (Lynozyfic), bispecific antibodies; ide-cel (Abecma), another CAR-T therapy; belantamab mafodotina (Blenrep); and earlier uses of already approved medications, such as Carvykti from the first line of treatment, Dara-VRd in the first treatment, and daratumumab in high-risk latent myeloma. Some may be under evaluation; Infarmed only publishes the decision at the end. Talk to your team about early access or clinical trials.

Rejected

Revlimid (lenalidomide) � With bortezomib and dexamethasone (VRd) as the first treatment for those who cannot undergo transplant Refused on 2020-07-14
The data presented did not allow for comparison with existing treatments. National guidance confirms that VRd is not funded in this situation. report ↗

Where are treatments carried out?

Tablets, injections and solutions (lenalidomide, pomalidomide, bortezomib, carfilzomib, daratumumab, isatuximab…): within the hematology departments of SNS hospitals, in day hospitals, or to take at home with pharmacy pickup. Each hospital decides how to apply approved medications, based on its pharmacy committee.

Bispecific antibodies (teclistamab, elranatamab): only in hospitals with a team and resources to treat it cytokine storm syndromeInflammatory reaction (fever, low blood pressure, shortness of breath) that can occur in the first few days of treatments that activate T lymphocytes, such as CAR-T and bispecific therapies. And neurotoxicity. The first doses are administered with close monitoring (at Elrexfio, 48 hours after each of the first 2 doses).

Autologous transplantRefer to hematology services with a stem cell transplant unit; the hematologist makes the referral.

CAR-TOnly in qualified centers. In October 2026, there were 6 (HealthNews, 28/10/2026):

  • Lisbon: IPO of Lisbon, ULS Santa Maria and ULS São José (accredited in 2026)
  • Porto: IPO do Porto and ULS São João
  • Coimbra: ULS Coimbra

Not all centers treat all diseases; the patient’s hematologist decides and refers. Patients from other regions (Algarve, Azores, Madeira, inland) are sent to these centers. See also the Hospital contacts.

The national guideline for myeloma (CNFT, 2022)

The National Commission for Pharmacy and Health Technology Assessment (Infarmed) published a guidance on myeloma medications in 2022. In summary:

  • First treatment, under 70 years old and candidates for transplant: 4 to 6 cycles of a triplet (VTd; VRd is the preferred clinical option, although off-label), cell harvest, autotransplantation with melphalan at high dose and consolidation; followed by maintenance with lenalidomide (at least 12 cycles, ideally up to 36).
  • 70 years or older, or without a transplant: First choice VMP (in a milder version for frail patients); VTd and VCd are alternatives; VRd is not funded in this situation.
  • Relapse: There is no ideal sequence; preferred medications that have not yet been used and funded (Dara-Vd, Dara-Rd, KRd, IxaRd, Kd, Rd or Pd), depending on whether the disease has progressed with lenalidomide and whether the patient is or is not frail.
  • Refractory to lenalidomide and bortezomib: pomalidomide with dexamethasone, daratumumab alone or Dara-Kd; some patients may undergo a second transplant if the first responded for at least 3 years.

The guidance for 2022: does not include CAR-T or the bispecifics approved thereafter. Guideline No. 11 of the CNFT ↗ · full search on the Infarmed website ↗